Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.38 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994172 | 0.81 | ERN1 (0.46) | ALDH1A1ERN1TDP1ATMSOS1 | |
| SCHEMBL2994940 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTCYP3A4HSD17B10KDM4E | |
| SCHEMBL1094404 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPTCYP3A4HSD17B10KDM4E | |
| SCHEMBL1414122 | 0.77 | NPC1 (0.47) | ALDH1A1MAPTCYP3A4HSD17B10KDM4E | |
| SCHEMBL13418991 | 0.75 | TDP1 (0.59) | ALDH1A1MAPTCYP3A4HSD17B10MAPK1 | |
| SCHEMBL30766458 | 0.72 | ALDH1A1 (0.38) | ALDH1A1MAPTCYP3A4ERN1MAPK1 | |
| SCHEMBL2073735 | 0.72 | MAPT (0.50) | ALDH1A1MAPTCYP3A4HSD17B10KDM4E | |
| SCHEMBL18370780 | 0.72 | ALDH1A1 (0.49) | ALDH1A1MAPTCYP3A4HSD17B10KDM4E | |
| SCHEMBL32665668 | 0.72 | XDH (0.50) | ALDH1A1MAPTCYP3A4HSD17B10KDM4E | |
| SCHEMBL1999504 | 0.72 | MAPT (0.49) | ALDH1A1MAPTCYP3A4HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240472-B1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-21 | — | — | EP | disclosed |
| EP-2240472-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF -SECRETASE (BACE) | Janssen Pharmaceutica NV (BE) | 2010-10-20 | — | — | EP | disclosed |
| US-7786116-B2 | 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-20090227581-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-10 | — | — | US | disclosed |
| WO-2009097401-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227581-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | ALDH1A1 4048/4885MAPT 57/4885CYP3A4 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.